HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target.

By C. Grávalos, A. Jimeno. Annals of Oncology, 2008

1,185 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Tumor Targeting via EPR: Strategies to Enhance Patient Responses (2018, background): “Blocking of HER2 signaling limits proliferation and induces apoptosis in tumor cells, thus decreasing the cell density in tumors [168,169].”
Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications (2014, positive): “Gravalos and Jimeno [30] in their study of 166 gastric cancer patients observed that HER2 overexpression was most commonly found in gastroesophageal junction (GEJ) tumors and tumors having intestinal type histology.”
A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets (2012, result): “These results suggest that KRAS ampli ﬁ cation in gastric cancer probably de ﬁ nes a speci ﬁ c subgroup of poor prognosis patients for which KRAS signalling in tumours is critical.”
Lnc RNA HOTAIR functions as a competing endogenous RNA to regulate HER2 expression by sponging miR-331-3p in gastric cancer (2014, background): “HER2 amplification and/or overexpression have been detected in approximately 20% to 30% of patients with breast and gastric cancer and correlates with poorer clinical outcomes [19,30,31].”